<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03071406</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-18786</org_study_id>
    <secondary_id>CA209-737</secondary_id>
    <nct_id>NCT03071406</nct_id>
  </id_info>
  <brief_title>Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma</brief_title>
  <official_title>A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness, safety, and tolerability of the drugs&#xD;
      nivolumab plus ipilimumab with or without the addition of stereotactic body radiation therapy&#xD;
      (SBRT). Nivolumab is an antibody (a type of human protein) that is being tested to see if it&#xD;
      will stimulate the body's immune system to work against tumor cells. This study will test an&#xD;
      investigational use of nivolumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are randomly assigned in a 1:1 ratio to Arm A (nivolumab + ipilimumab), or Arm B (nivolumab + ipilimumab + SBRT).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 weeks</time_frame>
    <description>Objective-response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1: including Complete Response (CR) rate, Partial Response (PR) rate, and Stable Disease (SD) rate will be calculated through exact binomial distribution with a 2-sided 95% confidence interval among patients who obtain a least one dose of study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>Median Progression Free Survival with 95% Confidence Interval. Progression is defined as progressive tumor lesions per immune-related Response Evaluation in Solid Tumors (irRECIST) definition, or appearance of one or more new Merkel cell carcinoma lesions, which can be local or distant in location from the irradiated lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Median Overall Survival with 95% Confidence Interval. The length of time from the start of treatment until death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Nivolumab + Ipilimumab + SBRT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nivolumab every 2 weeks and Ipilimumab every 6 weeks until progression or unacceptable toxicity. Stereotactic Body Radiation Therapy (SBRT) to be given at the start of week 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.</description>
    <arm_group_label>Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Arm B: Nivolumab + Ipilimumab + SBRT</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab 1 mg/kg/dose IV q6 weeks.</description>
    <arm_group_label>Arm A: Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_label>Arm B: Nivolumab + Ipilimumab + SBRT</arm_group_label>
    <other_name>YERVOY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy (SBRT)</intervention_name>
    <description>Stereotactic Body Radiation Therapy 24Gy in 3 fractions.</description>
    <arm_group_label>Arm B: Nivolumab + Ipilimumab + SBRT</arm_group_label>
    <other_name>SBRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status less than 2&#xD;
&#xD;
          -  Active disease measurable by CT, MRI or clinical exam.&#xD;
&#xD;
          -  Prior chemotherapy or immunotherapy will be allowed if new or persistent measurable&#xD;
             site(s) of disease are present.&#xD;
&#xD;
          -  Prior radiation therapy will be allowed if there is active measurable disease burden.&#xD;
&#xD;
          -  Must be either recurrent, unresectable or Stage IV American Joint Committee on Cancer&#xD;
             (AJCC) (7th edition) and have histologically confirmed Merkel cell carcinoma with at&#xD;
             least 2 distinct lesions in order to be eligible.&#xD;
&#xD;
          -  Must have at least 2 distinct lesions as documented by a complete physical examination&#xD;
             or imaging studies within 4 weeks prior to randomization. Imaging studies must include&#xD;
             a diagnostic CT scan of the involved disease sites and all known sites of resected&#xD;
             disease and brain magnetic resonance (MRI) or CT (brain CT allowable if MRI is&#xD;
             contraindicated or if there is no known history of resected brain lesions).&#xD;
&#xD;
          -  Tumor tissue from the core biopsy or resected site of disease must be provided for&#xD;
             biomarker analyses.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Grade 3 toxicity or use of infliximab with prior immunotherapy&#xD;
&#xD;
          -  Patients with active brain metastasis.&#xD;
&#xD;
          -  Active, known, or suspected autoimmune disease. Potential participants with type I&#xD;
             diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only&#xD;
             requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or&#xD;
             alopecia) not requiring systemic treatment are permitted to enroll.&#xD;
&#xD;
          -  Patients with prior history of non-Merkel cell carcinoma malignancies are excluded&#xD;
             except adequately treated basal cell, squamous cell skin cancer, chronic lymphocytic&#xD;
             leukemia or other indolent diseases not requiring therapy; adequately treated, with&#xD;
             curative intent, cancer from which the patient is currently in complete remission per&#xD;
             investigator's judgment; or patients with history of breast cancer and no evidence of&#xD;
             disease on hormonal therapy to prevent recurrence and patients with prostate cancer on&#xD;
             adjuvant hormonal therapy with undetectable PSA are eligible.&#xD;
&#xD;
          -  A condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalent) or other immunosuppressive medications within 14 days of&#xD;
             randomization. Inhaled or topical steroids are permitted in the absence of active&#xD;
             autoimmune disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sungjune Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mia Aoki</last_name>
    <phone>813-745-4377</phone>
    <email>Mia.Aoki@moffitt.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sungjune Kim</last_name>
    <phone>813-745-7898</phone>
    <email>sungjune.kim@moffitt.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren (Taylor) Michael</last_name>
      <phone>813-745-3104</phone>
      <email>Taylor.Michael@moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Sungjune Kim, M.D., Ph.D.</last_name>
      <phone>813-745-7898</phone>
      <email>sungjune.kim@moffitt.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sungjune Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jimmy Caudell, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nikhil Khushalani, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane Messina, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Trevor Rose, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis Harrison, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph Markowitz, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Brohl, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zeynep Eroglu, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evan Wuthrick, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Kulesza</last_name>
      <email>lauren.kulesza@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Dukagjin Blakaj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://moffitt.org/clinical-trials-research/</url>
    <description>Moffitt Cancer Center Clinical Trials website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 1, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2017</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Merkel cell carcinoma (MCC)</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Metastasis</keyword>
  <keyword>Stereotactic body radiation therapy (SBRT)</keyword>
  <keyword>Immunology</keyword>
  <keyword>Antibody</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Metastatic skin cancer</keyword>
  <keyword>Cutaneous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

